熱門資訊> 正文
Apellis III期Empaveli数据表明蛋白尿持续减少
2025-06-06 23:39
- New phase 3 data on Apellis Pharmaceuticals (NASDAQ:APLS) and Sobi's Empaveli (pegcetacoplan) indicated that the treatment led to proteinuria reduction that was sustained for a year.
- At week 26, there was a 68% proteinuria reduction for those on Empaveli compared to placebo, which was sustained at one year.
- Those on the drug also saw kidney function stabilization based on estimated glomerular filtration rate (eGFR).
- The VALIANT study is exploring the treatment for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
- Empaveli is currently approved for paroxysmal nocturnal hemoglobinuria.
More on Apellis Pharmaceuticals
- Apellis Pharmaceuticals: Have Some Patience
- Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript
- Apellis Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation
- Apellis Pharmaceuticals GAAP EPS of -$0.74 misses by $0.39, revenue of $166.8M misses by $28.08M
- Apellis Pharmaceuticals Q1 2025 Earnings Preview
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
